Interleukin-1 has opposing effects on connective tissue growth factor and tenascin-C expression in human cardiac fibroblasts

Matrix Biology

Volumn 32, Issue 3-4, 2013, Pages 208-214

  Maqbool, Azhar ^a,b   Hemmings, Karen E ^a,b   O'Regan, David J ^b,c   Ball, Stephen G ^a,b   Porter, Karen E ^a,b   Turner, Neil A ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Cardiac fibroblasts; Connective tissue growth factor; Interleukin 1; Signal transduction; Tenascin C

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1ALPHA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEONECTIN; OSTEOPONTIN; PHOSPHATIDYLINOSITOL 3 KINASE; STRESS ACTIVATED PROTEIN KINASE; TENASCIN; THROMBOSPONDIN 1; THROMBOSPONDIN 2; THROMBOSPONDIN 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CARDIAC FIBROBLAST; HEART ATRIUM APPENDAGE; HEART MUSCLE CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

CELLS, CULTURED; CONNECTIVE TISSUE GROWTH FACTOR; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-1ALPHA; MYOCARDIUM; MYOFIBROBLASTS; PHENOTYPE; RNA, MESSENGER; SIGNAL TRANSDUCTION; TENASCIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84876856286     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2013.02.003     Document Type: Article

References (62)

1. Abraham D.J., Shiwen X., Black C.M., Sa S., Xu Y., Leask A. Tumor necrosis factor α suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J. Biol. Chem. 2000, 275:15220-15225.
2. Ahmed M.S., Gravning J., Martinov V.N., von Lueder T.G., Edvardsen T., Czibik G., Moe I.T., Vinge L.E., Oie E., Valen G., Attramadal H. Mechanisms of novel cardioprotective functions of CCN2/CTGF in myocardial ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 2011, 300:H1291-H1302.
3. Beddy D., Mulsow J., Watson R.W., Fitzpatrick J.M., O'Connell P.R. Expression and regulation of connective tissue growth factor by transforming growth factor β and tumour necrosis factor α in fibroblasts isolated from strictures in patients with Crohn's disease. Br. J. Surg. 2006, 93:1290-1296.
4. Bradham W.S., Moe G., Wendt K.A., Scott A.A., Konig A., Romanova M., Naik G., Spinale F.G. TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. Am. J. Physiol. Heart Circ. Physiol. 2002, 282:H1288-H1295.
5. Chiquet-Ehrismann R., Chiquet M. Tenascins: regulation and putative functions during pathological stress. J. Pathol. 2003, 200:488-499.
6. Clark J.E., Sarafraz N., Marber M.S. Potential of p38-MAPK inhibitors in the treatment of ischaemic heart disease. Pharmacol. Ther. 2007, 116:192-206.
7. Daniels A., Van Bilsen M., Goldschmeding R., van Der Vusse G.J., van Nieuwenhoven F.A. Connective tissue growth factor and cardiac fibrosis. Acta Physiol. (Oxf) 2009, 195:321-338.
8. Deten A., Volz H.C., Briest W., Zimmer H.G. Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats. Cardiovasc. Res. 2002, 55:329-340.
9. Dobaczewski M., Bujak M., Zymek P., Ren G., Entman M.L., Frangogiannis N.G. Extracellular matrix remodeling in canine and mouse myocardial infarcts. Cell Tissue Res. 2006, 324:475-488.
10. Dobaczewski M., Gonzalez-Quesada C., Frangogiannis N.G. The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. J. Mol. Cell. Cardiol. 2010, 48:504-511.
11. El-Karef A., Yoshida T., Gabazza E.C., Nishioka T., Inada H., Sakakura T., Imanaka-Yoshida K. Deficiency of tenascin-C attenuates liver fibrosis in immune-mediated chronic hepatitis in mice. J. Pathol. 2007, 211:86-94.
12. Frangogiannis N.G. Matricellular proteins in cardiac adaptation and disease. Physiol. Rev. 2012, 92:635-688.
13. Frangogiannis N.G., Smith C.W., Entman M.L. The inflammatory response in myocardial infarction. Cardiovasc. Res. 2002, 53:31-47.
14. Frangogiannis N.G., Ren G., Dewald O., Zymek P., Haudek S., Koerting A., Winkelmann K., Michael L.H., Lawler J., Entman M.L. Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocardial infarcts. Circulation 2005, 111:2935-2942.
15. Goh F.G., Piccinini A.M., Krausgruber T., Udalova I.A., Midwood K.S. Transcriptional regulation of the endogenous danger signal tenascin-C: a novel autocrine loop in inflammation. J. Immunol. 2010, 184:2655-2662.
16. Gravning J., Orn S., Kaasboll O.J., Martinov V.N., Manhenke C., Dickstein K., Edvardsen T., Attramadal H., Ahmed M.S. Myocardial connective tissue growth factor (CCN2/CTGF) attenuates left ventricular remodeling after myocardial infarction. PLoS One 2012, 7:e52120.
17. Imanaka-Yoshida K., Hiroe M., Nishikawa T., Ishiyama S., Shimojo T., Ohta Y., Sakakura T., Yoshida T. Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. Lab. Invest. 2001, 81:1015-1024.
18. Imanaka-Yoshida K., Hiroe M., Yoshida T. Interaction between cell and extracellular matrix in heart disease: multiple roles of tenascin-C in tissue remodeling. Histol. Histopathol. 2004, 19:517-525.
19. Irwin M.W., Mak S., Mann D.L., Qu R., Penninger J.M., Yan A., Dawood F., Wen W.H., Shou Z., Liu P. Tissue expression and immunolocalization of tumor necrosis factor-α in postinfarction dysfunctional myocardium. Circulation 1999, 99:1492-1498.
20. Jugdutt B.I. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?. Circulation 2003, 108:1395-1403.
21. Kalembeyi I., Inada H., Nishiura R., Imanaka-Yoshida K., Sakakura T., Yoshida T. Tenascin-C upregulates matrix metalloproteinase-9 in breast cancer cells: direct and synergistic effects with transforming growth factor beta1. Int. J. Cancer 2003, 105:53-60.
22. Kennedy L., Liu S., Shi-wen X., Chen Y., Eastwood M., Sabetkar M., Carter D.E., Lyons K.M., Black C.M., Abraham D.J., Leask A. CCN2 is necessary for the function of mouse embryonic fibroblasts. Exp. Cell Res. 2007, 313:952-964.
23. Komatsubara I., Murakami T., Kusachi S., Nakamura K., Hirohata S., Hayashi J., Takemoto S., Suezawa C., Ninomiya Y., Shiratori Y. Spatially and temporally different expression of osteonectin and osteopontin in the infarct zone of experimentally induced myocardial infarction in rats. Cardiovasc. Pathol. 2003, 12:186-194.
24. Leask A., Holmes A., Black C.M., Abraham D.J. Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts. J. Biol. Chem. 2003, 278:13008-13015.
25. Leask A., Parapuram S.K., Shi-wen X., Abraham D.J. Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease?. J. Cell Commun. Signal. 2009, 3:89-94.
26. Lin J., Liliensiek B., Kanitz M., Schimanski U., Bohrer H., Waldherr R., Martin E., Kauffmann G., Ziegler R., Nawroth P.P. Molecular cloning of genes differentially regulated by TNF-alpha in bovine aortic endothelial cells, fibroblasts and smooth muscle cells. Cardiovasc. Res. 1998, 38:802-813.
27. Liu S., Shi-wen X., Abraham D.J., Leask A. CCN2 is required for bleomycin-induced skin fibrosis in mice. Arthritis Rheum. 2011, 63:239-246.
28. Long C.S. The role of interleukin-1 in the failing heart. Heart Fail. Rev. 2001, 6:81-94.
29. McCurdy S.M., Dai Q., Zhang J., Zamilpa R., Ramirez T.A., Dayah T., Nguyen N., Jin Y.F., Bradshaw A.D., Lindsey M.L. SPARC mediates early extracellular matrix remodeling following myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 2011, 301:H497-H505.
30. Midwood K., Sacre S., Piccinini A.M., Inglis J., Trebaul A., Chan E., Drexler S., Sofat N., Kashiwagi M., Orend G., Brennan F., Foxwell B. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat. Med. 2009, 15:774-780.
31. Mughal R.S., Warburton P., O'Regan D.J., Ball S.G., Turner N.A., Porter K.E. Peroxisome proliferator-activated receptor γ-independent effects of thiazolidinediones on human cardiac myofibroblast function. Clin. Exp. Pharmacol. Physiol. 2009, 36:478-486.
32. Nakahara H., Gabazza E.C., Fujimoto H., Nishii Y., D'Alessandro-Gabazza C.N., Bruno N.E., Takagi T., Hayashi T., Maruyama J., Maruyama K., Imanaka-Yoshida K., Suzuki K., Yoshida T., Adachi Y., Taguchi O. Deficiency of tenascin C attenuates allergen-induced bronchial asthma in the mouse. Eur. J. Immunol. 2006, 36:3334-3345.
33. Nakoshi Y., Hasegawa M., Sudo A., Yoshida T., Uchida A. Regulation of tenascin-C expression by tumor necrosis factor-α in cultured human osteoarthritis chondrocytes. J. Rheumatol. 2008, 35:147-152.
34. Nian M., Lee P., Khaper N., Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ. Res. 2004, 94:1543-1553.
35. Nishiura R., Noda N., Minoura H., Toyoda N., Imanaka-Yoshida K., Sakakura T., Yoshida T. Expression of matrix metalloproteinase-3 in mouse endometrial stromal cells during early pregnancy: regulation by interleukin-1alpha and tenascin-C. Gynecol. Endocrinol. 2005, 21:111-118.
36. Nowinski D., Hoijer P., Engstrand T., Rubin K., Gerdin B., Ivarsson M. Keratinocytes inhibit expression of connective tissue growth factor in fibroblasts in vitro by an interleukin-1α-dependent mechanism. J. Invest Dermatol. 2002, 119:449-455.
37. Nowinski D., Koskela A., Kiwanuka E., Bostrom M., Gerdin B., Ivarsson M. Inhibition of connective tissue growth factor/CCN2 expression in human dermal fibroblasts by interleukin-1alpha and beta. J. Cell. Biochem. 2010, 110:1226-1233.
38. Okamoto H., Imanaka-Yoshida K. Matricellular proteins: new molecular targets to prevent heart failure. Cardiovasc. Ther. 2012, 30:e198-e209.
39. Ponticos M., Holmes A.M., Shi-wen X., Leoni P., Khan K., Rajkumar V.S., Hoyles R.K., Bou-Gharios G., Black C.M., Denton C.P., Abraham D.J., Leask A., Lindahl G.E. Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen. Arthritis Rheum. 2009, 60:2142-2155.
40. Porter K.E., Turner N.A. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol. Ther. 2009, 123:255-278.
41. Porter K.E., Turner N.A., O'Regan D.J., Ball S.G. Tumor necrosis factor α induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. Cardiovasc. Res. 2004, 64:507-515.
42. Porter K.E., Turner N.A., O'Regan D.J., Balmforth A.J., Ball S.G. Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA. Cardiovasc. Res. 2004, 61:745-755.
43. Santiago J.J., Dangerfield A.L., Rattan S.G., Bathe K.L., Cunnington R.H., Raizman J.E., Bedosky K.M., Freed D.H., Kardami E., Dixon I.M. Cardiac fibroblast to myofibroblast differentiation in vivo and in vitro: expression of focal adhesion components in neonatal and adult rat ventricular myofibroblasts. Dev. Dyn. 2010, 239:1573-1584.
44. Sato A., Aonuma K., Imanaka-Yoshida K., Yoshida T., Isobe M., Kawase D., Kinoshita N., Yazaki Y., Hiroe M. Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. J. Am. Coll. Cardiol. 2006, 47:2319-2325.
45. Schellings M.W., Pinto Y.M., Heymans S. Matricellular proteins in the heart: possible role during stress and remodeling. Cardiovasc. Res. 2004, 64:24-31.
46. Shi-wen X., Stanton L.A., Kennedy L., Pala D., Chen Y., Howat S.L., Renzoni E.A., Carter D.E., Bou-Gharios G., Stratton R.J., Pearson J.D., Beier F., Lyons K.M., Black C.M., Abraham D.J., Leask A. CCN2 is necessary for adhesive responses to transforming growth factor-beta1 in embryonic fibroblasts. J. Biol. Chem. 2006, 281:10715-10726.
47. Sinfield J.K., Das A., O'Regan D.J., Ball S.G., Porter K.E., Turner N.A. p38 MAPK alpha mediates cytokine-induced IL-6 and MMP-3 expression in human cardiac fibroblasts. Biochem. Biophys. Res. Commun. 2013, 430:419-424.
48. Tamaoki M., Imanaka-Yoshida K., Yokoyama K., Nishioka T., Inada H., Hiroe M., Sakakura T., Yoshida T. Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am. J. Pathol. 2005, 167:71-80.
49. Tojyo I., Yamaguchi A., Nitta T., Yoshida H., Fujita S., Yoshida T. Effect of hypoxia and interleukin-1beta on expression of tenascin-C in temporomandibular joint. Oral Dis. 2008, 14:45-50.
50. Toma N., Imanaka-Yoshida K., Takeuchi T., Matsushima S., Iwata H., Yoshida T., Taki W. Tenascin-C-coated platinum coils for acceleration of organization of cavities and reduction of lumen size in a rat aneurysm model. J. Neurosurg. 2005, 103:681-686.
51. Trueblood N.A., Xie Z., Communal C., Sam F., Ngoy S., Liaw L., Jenkins A.W., Wang J., Sawyer D.B., Bing O.H., Apstein C.S., Colucci W.S., Singh K. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ. Res. 2001, 88:1080-1087.
52. Turner N.A. Therapeutic regulation of cardiac fibroblast function: targeting stress-activated protein kinase pathways. Future Cardiol. 2011, 7:673-691.
53. Turner N.A., Porter K.E. Regulation of myocardial matrix metalloproteinase expression and activity by cardiac fibroblasts. IUBMB Life 2012, 64:143-150.
54. 1A receptor internalisation. Cell. Signal. 2001, 13:269-277.
55. 2-adrenergic receptor stimulation increases proliferation of human cardiac fibroblasts via an autocrine mechanism. Cardiovasc. Res. 2003, 57:784-792.
56. Turner N.A., Mughal R.S., Warburton P., O'Regan D.J., Ball S.G., Porter K.E. Mechanism of TNFα-induced IL-1α, IL-1β and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones. Cardiovasc. Res. 2007, 76:81-90.
57. Turner N.A., Das A., Warburton P., O'Regan D.J., Ball S.G., Porter K.E. Interleukin-1α stimulates pro-inflammatory cytokine expression in human cardiac myofibroblasts. Am. J. Physiol. Heart Circ. Physiol. 2009, 297:H1117-H1127.
58. Turner N.A., Warburton P., O'Regan D.J., Ball S.G., Porter K.E. Modulatory effect of interleukin-1α on expression of structural matrix proteins, MMPs and TIMPs in human cardiac myofibroblasts: role of p38 MAP kinase. Matrix Biol. 2010, 29:613-620.
59. Turner N.A., Das A., O'Regan D.J., Ball S.G., Porter K.E. Human cardiac fibroblasts express ICAM-1, E-selectin and CXC chemokines in response to proinflammatory cytokine stimulation. Int. J. Biochem. Cell Biol. 2011, 43:1450-1458.
60. van Nieuwenhoven F.A., Turner N.A. The role of cardiac fibroblasts in the transition from inflammation to fibrosis following myocardial infarction. Vascul. Pharmacol. 2013, 58:185-190.
61. Yamamoto K., Dang Q.N., Kennedy S.P., Osathanondh R., Kelly R.A., Lee R.T. Induction of tenascin-C in cardiac myocytes by mechanical deformation. Role of reactive oxygen species. J. Biol. Chem. 1999, 274:21840-21846.
62. Yu F., Chou C.W., Chen C.C. TNF-α suppressed TGF-β-induced CTGF expression by switching the binding preference of p300 from Smad4 to p65. Cell. Signal. 2009, 21:867-872.